EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitSystematische ÜbersichtMetaanalyseOpen Access · CC BY 4.0

Apixaban Versus Low-Molecular-Weight Heparin for Cancer-Associated Venous Thromboembolism: A Systematic Review and Meta-Analysis

Sumit Aggarwal iD, Vikram Singh iD, Aayushi Bhasin, Sachit Anand iD, Heena Tabassum

Journal of Clinical Medicine · 08.07.2026 · 15 (14) · 5341

DOI: 10.3390/jcm15145341 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Clinical Medicine, online erschienen am 08.07.2026. Verfasst von Sumit Aggarwal und 4 weiteren Autor:innen. Beteiligte Einrichtung: Indian Council of Medical Research, New Delhi 110029, India. Die Arbeit nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Venous thromboembolism (VTE), particularly in the context of cancer-associated thrombosis (CAT), is a major cause of morbidity and mortality in patients with malignancy. While apixaban has emerged as a potential alternative to low-molecular-weight heparins (LMWHs), uncertainty remains regarding the consistency of its safety profile across different LMWH agents.

Methods

This systematic review and meta-analysis was conducted in accordance with PRISMA guidelines. A comprehensive literature search was performed across PubMed, Web of Science, and the Cochrane Central Register of Controlled Trials.

Results

Six randomized controlled trials were included. Apixaban was associated with a reduced risk of recurrent VTE (RR 0.66, 95% CI 0.45–0.96). However, safety outcomes varied depending on the LMWH comparator. Compared with dalteparin, apixaban was associated with a higher risk of clinically relevant non-major bleeding (CRNMB) (log RR 0.38; 95% CI 0.02 to 0.75), whereas, compared with enoxaparin, it was associated with a lower risk (log RR −0.49; 95% CI −0.96 to −0.02).

Conclusions

These findings suggest potential differences in safety profiles across individual LMWH agents. However, given the limited number of included trials and clinical heterogeneity, the results should be interpreted cautiously. Further large-scale studies are required to confirm these observations.

Schlagwörter

Stichwörter der Autor:innen

apixabancancer-associated thrombosislow-molecular-weight heparinmeta-analysisvenous thromboembolism

Autor:innen und Institutionen

  • Indian Council of Medical Research, New Delhi 110029, India.
  • All India Institute of Medical Sciences, New Delhi 110029, India.

ORCID-Profile: Sumit Aggarwal, Vikram Singh, Sachit Anand

Zitieren

APA

Aggarwal, S., Singh, V., Bhasin, A., Anand, S., & Tabassum, H. (2026). Apixaban Versus Low-Molecular-Weight Heparin for Cancer-Associated Venous Thromboembolism: A Systematic Review and Meta-Analysis. Journal of Clinical Medicine, 15(14), 5341. https://doi.org/10.3390/jcm15145341

Vancouver

Aggarwal S, Singh V, Bhasin A, Anand S, Tabassum H. Apixaban Versus Low-Molecular-Weight Heparin for Cancer-Associated Venous Thromboembolism: A Systematic Review and Meta-Analysis. Journal of Clinical Medicine. 2026;15(14):5341. doi:10.3390/jcm15145341

BibTeX
@article{Aggarwal2026,
  author = {Aggarwal, Sumit and Singh, Vikram and Bhasin, Aayushi and Anand, Sachit and Tabassum, Heena},
  title = {Apixaban Versus Low-Molecular-Weight Heparin for Cancer-Associated Venous Thromboembolism: A Systematic Review and Meta-Analysis},
  journal = {Journal of Clinical Medicine},
  year = {2026},
  volume = {15},
  number = {14},
  pages = {5341},
  doi = {10.3390/jcm15145341}
}
Kostenlos starten →